Protagenic Therapeutics- Warrants (13/04/2025) Return on Equity

Protagenic Therapeutics- Warrants (13/04/2025) posts a ROE of 316.93%. That is above the Industrials sector average of 20.56%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Industrials stocks, a ROE near 20.56% is typical. Protagenic Therapeutics- Warrants (13/04/2025)'s 316.93% is higher that level. That is roughly 1441.3% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Protagenic Therapeutics- Warrants (13/04/2025)'s ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 316.93%; use YoY and peer views to separate noise from signal.

Context for PTIXW's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 20.56%), and (3) consistency with growth and profitability. This page covers the first two; Protagenic Therapeutics- Warrants (13/04/2025)'s other metric pages and overview cover the third.

Judging Protagenic Therapeutics- Warrants (13/04/2025) against Industrials peers is usually better than using a market-wide rule of thumb. Business models inside Industrials are more comparable, which makes gaps in ROE easier to interpret. Start with 316.93% here, then scan peer and history charts to see if the gap is persistent.